Navigation Links
Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
Date:8/15/2008

CORAL GABLES, Fla., Aug. 15 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the second quarter and six months ended June 30, 2008.

"We continue to progress with our clinical development program for CPP-109," stated Patrick J. McEnany, Catalyst's Chief Executive Officer. "In particular, we are actively enrolling and dosing subjects in our U.S. Phase II clinical trials evaluating CPP-109 as a treatment for cocaine and methamphetamine addiction. We expect to have top-line results from our cocaine trial and our methamphetamine trial in the first quarter of 2009 and the third quarter of 2009, respectively."

"Additionally, we expect to launch other Phase II trials this year in indications which could include binge eating disorder and alcohol dependence. As we previously discussed, it is likely that Catalyst will seek partners for these indications."

Second Quarter 2008 Results

For the quarter ended June 30, 2008, the Company reported a net loss of $2,377,440, or $0.19 per basic and diluted share, compared to a net loss of $1,208,130, or $0.10 per basic and diluted share for the same period in 2007. Second quarter 2008 results included non-cash charges relating to stock-based compensation in the amount of $123,208, compared to $182,233 in the same period in 2007. For the six months ended June 30, 2008, the Company reported a net loss of $3,961,487, or $0.32 loss per basic and diluted share, compared to a net loss of $2,460,208, or $0.20 loss per basic and diluted share, for the same period in 2007. Results for the first six months of 2008 included non-cash charges relating to stock-based compensation in the amount of $386,612, compared to $382,601 in
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Controlling the size of nanoclusters: First step in making new catalysts
2. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
3. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
4. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
5. Experiments reveal unexpected activity of fuel cell catalysts
6. Using catalysts to stamp nanopatterns without ink
7. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
8. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, announced today that a Company overview will ... Pharmaceuticals Industry Conference, to be held at the Conference ... Dane R. Saglio, Chief Financial Officer, will present ...
... Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in ... issuance of its,21st US Patent entitled "Apparatus and Method ... Point Spread,Function of the Detected Light," dated November 4, ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) , ...
... CRY ), a,biomaterials, medical device and tissue processing company, ... Annual Piper Jaffray Health,Care Conference at The New York Palace ... Anderson, president and chief executive officer of CryoLife,Inc., will provide ... 2:30 p.m. Eastern Time. , ...
Cached Biology Technology:EntreMed to Present at the New York Society of Security Analysts Industry Conference 2Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office 2Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office 3CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference 2
(Date:4/23/2014)... 2014 A biomedical engineer at the University of ... to make blood transfusions safer. His work is supported ... of Health (NIH). , Blood transfusions save millions ... medicine,s absolute necessities. Without them, for instance, routine surgeries ... perfect, however. There,s strong evidence that transfusions of red ...
(Date:4/23/2014)... a 2 million Food Standards Agency (FSA) project to ... industry workers. , Norovirus outbreaks can rapidly affect ... of frozen strawberries infected 11,000 people in Germany, but ... which strains cause infection and which foods are the ... Researchers will produce data that will help the FSA ...
(Date:4/22/2014)... Gables, Fla. (April 21, 2014) -- There are all ... their feathers and spread their colorful tails; satin bowbirds ... with blue and shiny objects; and European bitterling males ... species has evolved a unique method to communicate with ... "Signaling can have profound fitness implications ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Best practices in communication for the animal world 2Best practices in communication for the animal world 3
... WASHINGTON While acupuncture is used widely to treat ... health benefits are not understood. In a series of ... demonstrating how acupuncture can significantly reduce the stress hormone ... , The latest study was published today in the ...
... Traveling into uncharted territory in search of food can ... benefit by moving through their habitat with relatives who ... that leaders in bottlenose dolphin groups in the Florida ... dolphins that follow them, according to research published March ...
... 12, 2013 Albuquerque, NM (UNM Cancer Center) ... kills most people. That,s why cancer researchers vigorously search ... cancer. The research team co-led by Angela Wandinger-Ness, PhD, ... Mexico Cancer Center has found a chemical compound that ...
Cached Biology News:Series of studies first to examine acupuncture's mechanisms of action 2Scientists discover novel chemical that controls cell behavior 2Scientists discover novel chemical that controls cell behavior 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: